Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in
combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation
(alloHCT) for prevention of relapse of childhood myeloid malignancies.